Skip to main content
. 2023 Mar 31;66(2):E170–E180. doi: 10.1503/cjs.010021

Table 2.

Study characteristics and baseline demographic characteristics of patients with hip fracture who received a direct oral anticoagulant before or after implementation of a vitamin K antagonist–reversal protocol, and of patients who did not receive an anticoagulant (control)

Study Study design Inclusion criteria Reversal protocol No. of patients Age, mean ± SD (range), yr Female sex, no. of patients



Control DOAC Control DOAC Control DOAC
Schermann et al.,20 2019

 CRIF Retrospective cohort Proximal hip fracture 24–36 h delay: rivaroxaban, apixaban; 12–24 h delay: dabigatran 977 60 82.7 ± 8 86.1 ± 5.7 762 44

 HA Retrospective cohort Proximal hip fracture 24–36 h delay: rivaroxaban, apixaban; 12–24 h delay: dabigatran 489 29 82.8 ± 7.6 86.2 ± 7.1 335 16

Schuetze et al.,29 2019 Retrospective cohort Inter- or subtrochanteric hip fracture Surgery within 24 h of admission, no reversal 146 52 NR NR NR NR

Franklin et al.,14 2018 Retrospective cohort Hip fracture, 60–89 yr of age Surgery within 48 h of admission, no reversal 76 19 NR NR 32 8

Mullins et al.,27 2018 Retrospective cohort Hip fracture No time delay to surgery, no reversal 62 63 85 (66–100) NR NR 47

Weighted total, no. (%) NA NA NA 1750 223 82.8 86.1 1542 (73.2) 171 (67.3)

CRIF = closed reduction internal fixation; DOAC = direct oral anticoagulant; HA = hemiarthroplasty; NA = not available; NR = not recorded; SD = standard deviation.